Disclaimer: Investments in RNAi Therapeutics are highly risky and not suited for most people.The purpose of the blog and model portfolio is to convey a sense of the dynamics in the field and is NOT an endorsement for making related investments. I also have financial interests in some of the companies included in the portfolio. I do not, however, have short positions in any of those.
Wednesday, January 13, 2010
RNAi Therapeutics Portfolio Update: mdRNA (Sell)
mdRNA announced today updates on results in mice for their liposomally delivered RNAi Therapeutics candidates for solid cancers. They also said to have entered into an "early collaborative effort with a major international pharmaceutical company". While not negative news for sure, both types of news items would appear to make the 75% run-up in shares this morning to be an over-reaction, especially given the one-month window it has to find additional funding. I will therefore take a trading profit at $1.71, and possibly look to re-enter the stock, maybe after an opportunistic financing following today's announcement.
Subscribe to:
Post Comments (Atom)
2 comments:
Guru
Look back to October and the MRNA press releases..This is the same rodent data with a different spin..
What I wanted to see was the primate data and it was not even in the latest release.
Saying they are collaborating again?.Why would a shareholder not expect them to be doing that 100% of the time!
I felt the ALNY news last week was interesting and it got no press.
Excellent call Dirk!
They got their financing then.
The terms could have been worse.
Post a Comment